Significance of serum VIP and PACAP in multiple sclerosis: an exploratory case-control study.

Maha S Al-KeilaniBasima A AlmomaniNour A Al-SawalhaMajdi Al QawasmehSaied A Jaradat

Published in: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2021)

VIP serum levels are decreased in MS patients and can be used to differentiate between MS patients and healthy controls. Further studies with larger sample sizes are required to investigate VIP as a marker to reflect MS disease progression.

Keyphrases

multiple sclerosis
end stage renal disease
mass spectrometry
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
white matter